NEW YORK, USA: Pfizer has announced the successful completion of its acquisition of Medivation. As of the tender offer expiration, 115,574,041 shares of Medivation common stock were validly tendered, representing approximately 69.1 percent of the shares outstanding and have been accepted for payment under the terms of the tender offer for US$ 81.50 per share in cash, without interest, subject to any required withholding of taxes.
In addition, notices of guaranteed delivery have been delivered for 17,659,861 shares of Medivation common stock, representing approximately 10.6 percent of the shares outstanding. Following its acceptance of the tendered shares, Pfizer completed its acquisition of Medivation through a second-step merger. Pfizer and its wholly-owned subsidiary accepted for payment and will promptly pay for all shares validly tendered and not validly withdrawn.
“Pfizer and Medivation are now one unified team combining research and resources to combat cancer.”
“This acquisition represents a rare opportunity to expand our business offering with an attractive pipeline and with XTANDI, an important medicine for men with prostate cancer “
“We welcome our new Medivation colleagues to the team and look forward to continuing the successful partnership with Astellas for XTANDI, ” said Albert Bourla, group president at Pfizer Innovative Health. “Given the breadth of Pfizer’s existing oncology portfolio and emerging immuno-oncology pipeline, Medivation’s assets will potentially benefit from many novel and productive combinations. Together, we are well positioned to becoming a leading oncology company, speeding cures and making accessible breakthrough medicines to patients – our number one priority.”